- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07633938
The Effect of Eyelid Support Plate Assisted Eyelid Massage on Meibomian Gland Dysfunction: a Randomized Controlled Trial
8 juni 2026 bijgewerkt door: Zhongshan Ophthalmic Center, Sun Yat-sen University
This study aims to conduct a randomized controlled clinical trial to compare the efficacy of a new type of massage device - eyelid support plate and glass rod assisted eyelid massage in improving MGD related dry eye symptoms, and evaluate the comfort and efficiency of both treatments, providing evidence-based support for clinical work
Studie Overzicht
Toestand
Nog niet aan het werven
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Geschat)
142
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Qi Fu
- Telefoonnummer: 86+66619334
- E-mail: fuqi@gzzoc.com
Studie Locaties
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Zhongshan Ophthalmology Center, Sun Yat sen University
-
Contact:
- Bishan Tian
- Telefoonnummer: 86+66619334
- E-mail: tianbishan@gzzoc.com
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Voluntarily participate and sign an informed consent form;
- Age range: 18 to 60 years old;
- Meet the diagnostic criteria for dry eye in the International Society of Tears and Ocular Surface (TFOS) Dry Eye Symposium (DEWS) II ;
- 1/3 or more of the meibomian gland openings are blocked or the secretion characteristics of the meibomian gland are abnormal;
- The best corrected visual acuity for each eye is ≥ 0.5;
- Eye pressure (IOP) ≥ 5mmHg and ≤ 21mmHg per eye;
- Women with reproductive potential agree to use reliable contraceptive methods during the study period;
- Willing and able to complete all planned research visits and follow the guidance of the researchers.
Exclusion Criteria:
- Contact lens use: Having used contact lenses within 14 days prior to the screening visit, or refusing to commit to discontinuing contact lens use during the study period (within the next 2 months);
- Had undergone corneal refractive surgery (e.g., LASIK/SMILE), other corneal surgeries, cataract surgery, anti-glaucoma surgery, or fundoscopic surgery within 12 months prior to enrollment screening;
- Participation in other medical studies within 3 months prior to enrollment screening;
Presence of any of the following active ocular diseases at present or within 3 months prior to screening: I) Acute allergic conjunctivitis; II) Infection (by bacteria, viruses, fungi, etc.); III) Inflammation (e.g., keratitis, retinitis).
Meningitis, choroiditis, uveitis, scleritis, etc.;
- Eyelid abnormalities affecting eyelid function (such as ptosis, blepharospasm, entropion, ectropion, etc.);
- Extensive ocular surface scars or conditions that may compromise ocular surface integrity (e.g., Stevens-Johnson syndrome, history of chemical burns, persistent corneal epithelial defects, history of ocular trauma, etc.);
- Currently or previously diagnosed with glaucoma, or undergoing treatment with anti-glaucoma medications;
- Has used any of the following ocular medications within the past 1 month: immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or perfluorohexyloctane;
- Has received any of the following non-pharmacological treatments for dry eye within the past month: meibomian gland massage, deep eyelid margin cleansing, intense pulsed light therapy, or thermal pulsation therapy;
- During pregnancy or lactation;
- Neurological or psychiatric disorders (moderate to severe anxiety, depression, and sleep disorders);
- Uncontrolled ocular or systemic diseases;
- History of epilepsy;
- The investigator determines that the subject is not suitable for participation in this study.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: glass rod group
Implement glass rod assisted eyelid massage for a total of 4 times
|
The participants of control group receive sodium hyaluronate eye drops 4 times a day for 8 weeks, and receive glass rod assisted eyelid massage based on the group standard of "Meibomian gland massage operation procedure" (T/GDPMAA003-2023) every 2 weeks, for a total of 4 times.
Follow up evaluations will be conducted at weeks 4 and 8
|
|
Experimenteel: eyelid support plate group
Implement eyelid support plate assisted eyelid massage for a total of 4 times.
|
The participants of experimental group receive sodium hyaluronate eye drops in both eyes four times a day for 8 weeks, and receive eyelid support plate assisted eyelid massage based on the group standard of Meibomian gland massage procedure (T/GDPMAA003-2023) every two weeks for a total of four times.
Follow up evaluations will be conducted at weeks 4 and 8.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean change from baseline in Ocular Surface Disease Index (OSDI) score at week 8
Tijdsspanne: Baseline, week 4, week 8
|
The OSDI is a 12-item patient-reported outcomes questionnaire, which to provide a rapid assessment of the range of ocular surface symptoms, including symptoms related to chronic dry eye, their severity, and their impact on the patient's ability to function.Each item is rated based on the frequency of symptoms in the past week: never (0 points) → sometimes (1 point) → half the time (2 points) → most of the time (3 points) → always (4 points),total score 0-100 points.The higher the score, the more obvious the dry eye symptoms.
|
Baseline, week 4, week 8
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in first non-invasive tear film break time
Tijdsspanne: Baseline, week 4, week 8
|
The time (in seconds) from the blink that evenly distributed the fluorescein to the appearance of the first tear breakup was recorded.
First non-invasive tear film rupture time (NIBUTf) was measured using an ocular surface analyzer (Keratography 5M, Oculus, Germany),
|
Baseline, week 4, week 8
|
|
proportion of Ocular Surface Disease Index (OSDI) scores showing a change ≥10 points from baseline at week 8
Tijdsspanne: Baseline, week 4, week 8
|
The OSDI is a 12-item patient-reported outcomes questionnaire, which to provide a rapid assessment of the range of ocular surface symptoms, including symptoms related to chronic dry eye, their severity, and their impact on the patient's ability to function.Each item is rated based on the frequency of symptoms in the past week: never (0 points) → sometimes (1 point) → half the time (2 points) → most of the time (3 points) → always (4 points),total score 0-100 points.The higher the score, the more obvious the dry eye symptoms.
|
Baseline, week 4, week 8
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Average operating time of eyelid massage (min)
Tijdsspanne: Baseline, week 2, week 4, week 6
|
Record the operating time of each eyelid massage treatment in two groups (after completing surface anesthesia, from the start of eyelid massage to the completion of squeezing the upper and lower eyelids of both eyes, each eyelid is squeezed twice), timed by the same timer, and after the timer is over, the operating time (min) is recorded after verification by two researchers.
|
Baseline, week 2, week 4, week 6
|
|
change in non-invasive lacrimal height measurement(NITMH)
Tijdsspanne: Baseline, week 4, week 8
|
Non-invasive lacrimal height measurement(NITMH)(mm) using an ocular surface analyzer (Keratography 5M, Oculus, Germany)
|
Baseline, week 4, week 8
|
|
Change in meibomian gland absence status
Tijdsspanne: Baseline, week 4, week 8
|
Measurement of meibomian gland deficiency using an ocular surface analyzer (Keratography 5M, Oculus, Germany).
Grading criteria for meibomian gland deficiency: 0 points (normal)=no meibomian gland deficiency, 1 point (mild)=meibomian gland deficiency ratio less than 1/3, 2 points (moderate)=meibomian gland deficiency ratio between 1/3 and 2/3, 3 points (severe)=meibomian gland deficiency ratio greater than 2/3.
Determine the extent and severity of meibomian gland deficiency, calculate the sum of upper and lower eyelid grading scores for each eye, with a total score range of 0-6 points.
|
Baseline, week 4, week 8
|
|
Change in lipid layer thickness (LLT)
Tijdsspanne: Baseline, week 4, week 8
|
Evaluation of lipid layer yhickness (LLT)(nm) using LipiView
|
Baseline, week 4, week 8
|
|
Change in partial blink frequency
Tijdsspanne: Baseline, week 4, week 8
|
Evaluation of partial blink frequency (%) using LipiView.
|
Baseline, week 4, week 8
|
|
Changes in Meibomian gland discharge ability score
Tijdsspanne: Baseline, week 4, week 8
|
Apply force to the eyeball within the range of 5 meibomian gland openings outside and in the center of the lower eyelid eyelash line, and observe the number of meibomian gland openings that can discharge meibomian gland secretions.
Grading criteria: 0 points (normal)=all 5 meibomian gland openings excrete secretions, 1 point (mild)=3 or 4 meibomian gland openings excrete secretions, 2 points (moderate)=1 or 2 meibomian gland openings excrete secretions, 3 points (severe)=no meibomian gland openings excrete secretions,The higher the score, the worse the discharge ability.
|
Baseline, week 4, week 8
|
|
Change in score of meibomian gland secretions
Tijdsspanne: Baseline, week 4, week 8
|
Scoring by operator based on secretion characteristics.
Grading criteria:0 points (normal)=clear and transparent liquid secretion,1 point (mild)=cloudy liquid secretion,2 points (moderate)=cloudy granular secretion,3 points (severe)=thick and toothpaste like secretion.The higher the score, the worse the quality of the secretion
|
Baseline, week 4, week 8
|
|
comfort scores for four sessions of eyelid massage in two groups
Tijdsspanne: Baseline, week 2, week 4, week 6
|
Use the Visual Analog Scale (VAS) to score the comfort of the operation.The scale is mainly composed of a 100mm straight line, with one end representing "completely painless" and the other end representing "the most severe pain imaginable" or "extreme pain".
The score range is from 0 to 100, where 0 represents complete painlessness and 100 represents the most severe pain experienced by the patient.
Patients will be asked to mark the corresponding position on this line (using an "X") to represent the intensity of pain they experienced at that time.
Within 1 minute after each operation, have participants mark the corresponding position on the scale to indicate the intensity of their pain at that time, and promptly record each result.
|
Baseline, week 2, week 4, week 6
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 juli 2026
Primaire voltooiing (Geschat)
1 juli 2027
Studie voltooiing (Geschat)
1 september 2027
Studieregistratiedata
Eerst ingediend
2 juni 2026
Eerst ingediend dat voldeed aan de QC-criteria
2 juni 2026
Eerst geplaatst (Werkelijk)
8 juni 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
11 juni 2026
Laatste update ingediend die voldeed aan QC-criteria
8 juni 2026
Laatst geverifieerd
1 mei 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026KYPJ065
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
JA
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .